TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7755005

Group type: EXPERIMENTAL
Intervention: Treatment
Number of subjects: 0
Study: 3294285

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 31199173

Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: adalimumab
Number of subjects: 0
Study: 27967273

Group type: EXPERIMENTAL
Intervention: Variable Unilateral Multidirectional (VUMD) movements
Number of subjects: 48

Group type: COMPARATOR
Intervention: Constant Bilateral Vertical (CBV) movement (squat)
Number of subjects: 48
Study: 25809332

Group type: EXPERIMENTAL
Intervention: Pectin 24 g powder/d (n=46)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 87
Study: 22939929

Group type: EXPERIMENTAL
Intervention: High height z-score trajectory
Number of subjects: 170

Group type: COMPARATOR
Intervention: Low height z-score trajectory with high BNP trajectory
Number of subjects: 170

Group type: COMPARATOR
Intervention: Serious adverse events during the trial
Number of subjects: 170

Group type: COMPARATOR
Intervention: Extracorporeal membrane oxygenation during neonatal hospitalization
Number of subjects: 170

Group type: COMPARATOR
Intervention: Supplemental oxygen at discharge
Number of subjects: 170
Study: 22303576

Group type: EXPERIMENTAL
Intervention: Dietetic treatment for childhood obesity (8 sessions of an 8-hour family-centred group treatment programme based on behavioural change techniques)
Number of subjects: 107

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 107
Study: 18692837

Group type: EXPERIMENTAL
Intervention: Resectoscopic excision of the complete septum starting from the vaginal interoitus
Number of subjects: 32

Group type: COMPARATOR
Intervention: Cold knife excision of the vaginal part followed by resectoscopic excision of the cervical and uterine parts
Number of subjects: 32
Study: 16858177

Group type: EXPERIMENTAL
Intervention: Operation
Number of subjects: 160

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 160
Study: 12775001

Group type: EXPERIMENTAL
Intervention: Giving-way trial
Number of subjects: 1

Group type: COMPARATOR
Intervention: Non-giving-way trials (n = 5)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Healthy subjects (n = 20)
Number of subjects: 1
Study: 11059704

Group type: EXPERIMENTAL
Intervention: Behavioral audiometric follow-up testing for high-risk infants
Number of subjects: 7259

Group type: EXPERIMENTAL
Intervention: Behavioral audiometric follow-up testing for well-baby nursery infants
Number of subjects: 7259

Group type: EXPERIMENTAL
Intervention: Factors predicting noncompliance with follow-up
Number of subjects: 7259

Group type: EXPERIMENTAL
Intervention: Behavioral hearing assessment protocols for validation
Number of subjects: 7259
Study: 9327371

Group type: EXPERIMENTAL
Intervention: Standard plus supplemental vitamin A (2.6 mumol/l [2500 IU] orally each day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Standard amount of vitamin A
Number of subjects: 14
Study: 8461970

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied 60 ms prior to expected onset of control saccades.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) with varying stimulus intensities.
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Express saccades in a 'gap' paradigm (mean saccadic reaction times of 107-141 ms).
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Non-targeted saccades in darkness in response to an auditory stimulus.
Number of subjects: 15
Study: 3462380

Group type: EXPERIMENTAL
Intervention: Megadose ascorbic acid supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31665619

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation intervention (exercise, cognitive and dual task training, social events)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation intervention
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (community sample of eleven individuals with premanifest HD receiving no intervention)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 18
Study: 29934956

Group type: EXPERIMENTAL
Intervention: BBG-D
Number of subjects: 30

Group type: COMPARATOR
Intervention: SWST
Number of subjects: 30
Study: 27282488

Group type: EXPERIMENTAL
Intervention: Dithiothreitol (DTT) treatment
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal saline solution treatment
Number of subjects: 70
Study: 23919955

Group type: EXPERIMENTAL
Intervention: Distress Thermometer (DT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HADS (Hospital Anxiety and Depression Scale)
Number of subjects: 0
Study: 22717217

Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg (three capsules daily with meals)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg (intent-to-treat analysis)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Placebo (intent-to-treat analysis)
Number of subjects: 435
Study: 20524987

Group type: EXPERIMENTAL
Intervention: TZP-101 80 μg kg(‐1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 18669453

Group type: EXPERIMENTAL
Intervention: Chemotherapy (fluorouracil/leucovorin) with radiotherapy (50 Gy) and adjuvant for 16 weeks after surgery (CRT group, n = 98)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Radiotherapy alone (50 Gy; RT group, n = 109)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: CRT group
Number of subjects: 207

Group type: COMPARATOR
Intervention: RT group
Number of subjects: 207
Study: 16685905

Group type: EXPERIMENTAL
Intervention: Incorporation of temporal information into machine learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discriminative feature selection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical and neuroscientific validation
Number of subjects: 0
Study: 12892687

Group type: EXPERIMENTAL
Intervention: Vaginal ring releasing oestradiol acetate at a rate equivalent to 50 microg/day
Number of subjects: 159

Group type: COMPARATOR
Intervention: Oral oestradiol 1 mg/day
Number of subjects: 159
Study: 10790902

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Assessment Only (AO)
Number of subjects: 250
Study: 8887015

Group type: EXPERIMENTAL
Intervention: Benfluorex (B)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 68
Study: 14589602

Group type: EXPERIMENTAL
Intervention: Malingering group (combined financial incentive and no financial incentive, N = 57)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Malingering group (M, N = 57)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (C, N = 28)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Closed head injury patients (CHI, N = 18)
Number of subjects: 104
Study: 6518461

Group type: EXPERIMENTAL
Intervention: Quinaglute Dura‐Tabs (Berlex Laboratories, Inc.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Bolar quinidine gluconate tablets (Bolar Pharmaceutical Company)
Number of subjects: 16
Study: 31036398

Group type: EXPERIMENTAL
Intervention: Patient skin sites
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Provider hands
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Environmental contamination at case 2 start
Number of subjects: 40

Group type: COMPARATOR
Intervention: Stopcock contamination rate
Number of subjects: 40
Study: 29526860

Group type: EXPERIMENTAL
Intervention: expanded Constraint‐Induced Movement Therapy (eCIMT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 21

Group type: COMPARATOR
Intervention: placebo‐control procedure
Number of subjects: 21
Study: 26497447

Group type: EXPERIMENTAL
Intervention: Positive Valence Training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control Training
Number of subjects: 61
Study: 24886549

Group type: EXPERIMENTAL
Intervention: Usual care plus extra counselling sessions through phone calls during the first month of quit attempt
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study: 23359966

Group type: EXPERIMENTAL
Intervention: External application of Compound Tripterygium wilfordii (CTW)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 20518695

Group type: EXPERIMENTAL
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Biliary Stenting (BS)
Number of subjects: 27
Study: 17577019

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1622
Study: 16275528

Group type: EXPERIMENTAL
Intervention: Dipyridamole/exercise stress MCE
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Quantitative MCE
Number of subjects: 90

Group type: COMPARATOR
Intervention: Exercise alone
Number of subjects: 90
Study: 12549945

Group type: EXPERIMENTAL
Intervention: On-site antifungal susceptibility testing (AST)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Off-site antifungal susceptibility testing (AST)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: NCCLS methodology (broth microdilution)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: AST performed
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: AST performed on blood specimens
Number of subjects: 171
Study: 10621930

Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.4 mg/day
Number of subjects: 494

Group type: COMPARATOR
Intervention: Cerivastatin 0.2 mg/day
Number of subjects: 494
Study: 8637188

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 36
Study: 1697272

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha treatment
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Laparoscopic instillation of prostaglandin F2 alpha
Number of subjects: 14
Study: 7440763

Group type: EXPERIMENTAL
Intervention: Fenofibrate (300 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fenofibrate with urine alkalinization
Number of subjects: 10
Study: 31553693

Group type: EXPERIMENTAL
Intervention: BuMel (busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue)
Number of subjects: 287

Group type: COMPARATOR
Intervention: VAI plus WLI (vincristine, dactinomycin, and ifosfamide with whole-lung irradiation)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: BuMel
Number of subjects: 287

Group type: COMPARATOR
Intervention: VAI plus WLI
Number of subjects: 287
Study: 28137754

Group type: EXPERIMENTAL
Intervention: r-hFSH/r-hLH
Number of subjects: 939

Group type: COMPARATOR
Intervention: r-hFSH
Number of subjects: 939
Study: 25376617

Group type: EXPERIMENTAL
Intervention: IBI‐20089 (6.9 mg or 13.8 mg TA) followed by ranibizumab (0.5 mg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination therapy (IBI‐20089 and ranibizumab)
Number of subjects: 120
Study: 23574881

Group type: EXPERIMENTAL
Intervention: PL plus TachoSil (group 1: 26 patients)
Number of subjects: 55

Group type: COMPARATOR
Intervention: PL without TachoSil (group 2: 29 patients)
Number of subjects: 55
Study: 22242343

Group type: EXPERIMENTAL
Intervention: Minimally invasive TLIF (group B)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Traditional open TLIF (group A)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study: 19822956

Group type: EXPERIMENTAL
Intervention: XbaI(‐) carriers
Number of subjects: 240
Study: 16923176

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 971

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 971
Study: 15095932

Group type: EXPERIMENTAL
Intervention: Nonenteric-coated aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa receptor inhibitors, unfractionated heparin (UFH), and clopidogrel (Plavix)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers, nitrates, antiplatelet agents, and antithrombin therapy (UFH or low-molecular-weight heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa receptor inhibitors (tirofiban, eptifibatide, abciximab)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolytics or primary PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early invasive management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early invasive or early conservative therapy
Number of subjects: 0
Study: 12607672

Group type: EXPERIMENTAL
Intervention: Cardiotomy suction
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cell-saving suction device
Number of subjects: 13

Group type: COMPARATOR
Intervention: Dual-filter group (21-microm filter attached in series)
Number of subjects: 13
Study: 9768766

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg (Group G)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Droperidol 50 microg/kg (Group D)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg plus Droperidol 50 microg/kg (Group GD)
Number of subjects: 180
Study: 7618724

Group type: EXPERIMENTAL
Intervention: Cold saline at 8-11 degrees C
Number of subjects: 48

Group type: COMPARATOR
Intervention: Room temperature saline
Number of subjects: 48
Study: 2096479

Group type: EXPERIMENTAL
Intervention: Dienogest
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Norethisterone
Number of subjects: 35

Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pretherapeutic cycles
Number of subjects: 35
Study: 727426

Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 101

Group type: COMPARATOR
Intervention: Enflurane anaesthesia
Number of subjects: 101
Study: 31915044

Group type: EXPERIMENTAL
Intervention: Online-group intervention (12-module webinar-based group intervention focusing on suicide bereavement-related themes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 0
Study: 30661477

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB) combined with medical therapy
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 100
Study: 27179291

Group type: EXPERIMENTAL
Intervention: Community-based advocacy, learning, and social support intervention
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 93
Study: 25636316

Group type: EXPERIMENTAL
Intervention: Community health worker intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Minimal intervention group
Number of subjects: 220
Study: 23298776

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progressive muscle relaxation training (PMRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (CBT and PMRT)
Number of subjects: 0
Study: 21868796

Group type: EXPERIMENTAL
Intervention: Ice therapy, NSAIDs, stretching and strengthening program
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ice therapy, NSAIDs, stretching and strengthening program, reinforced by acupuncture treatment
Number of subjects: 38
Study: 18715283

Group type: EXPERIMENTAL
Intervention: NTX 0.125 mg
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: NTX 0.250 mg
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 17917992

Group type: EXPERIMENTAL
Intervention: 8 hours of training emphasizing interviewing behaviours in the diagnosis and treatment of depression and GAD
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 16
Study: 15301689

Group type: EXPERIMENTAL
Intervention: 2 x 2 table tutorial
Number of subjects: 184

Group type: COMPARATOR
Intervention: Frequency tree tutorial
Number of subjects: 184
Study: 11499206

Group type: EXPERIMENTAL
Intervention: Community early defibrillation with AEDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control groups without AEDs
Number of subjects: 0
Study: 9552221

Group type: EXPERIMENTAL
Intervention: Oral enterically coated amoxicillin-clavulanic acid (1 g + 250 mg, t.i.d.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. methylprednisolone (40 mg/day) and oral placebo (t.i.d.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both i.v. methylprednisolone and oral amoxicillin-clavulanic acid as above
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral enterically coated amoxicillin-clavulanic acid
Number of subjects: 30

Group type: COMPARATOR
Intervention: i.v. methylprednisolone
Number of subjects: 30
Study: 29633349

Group type: EXPERIMENTAL
Intervention: Metformin (n = 188)
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo (n = 182)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Metformin treatment (n = 312)
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Metformin treatment (n = 188)
Number of subjects: 370
Study: 28443383

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei strain Shirota (LcS) - 100 ml of LcS-fermented milk daily for 8 weeks prior to and 3 weeks after the exam
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo - non-fermented placebo milk daily for 8 weeks prior to and 3 weeks after the exam
Number of subjects: 94
Study: 26311751

Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Not on medications at first GTC
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Older age at enrollment
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Duration of the shortest burst on baseline EEG
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Initial treatment response
Number of subjects: 446
Study: 24045248

Group type: EXPERIMENTAL
Intervention: Regimen B (caudocranial scan direction using a patient-specific contrast formula)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Regimen A (craniocaudal scan direction with 120 mL contrast)
Number of subjects: 320
Study: 19951554

Group type: EXPERIMENTAL
Intervention: L-arginine 200 mg group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: L-arginine 400 mg group
Number of subjects: 29
Study: 17530931

Group type: EXPERIMENTAL
Intervention: Low intensity/high volume (LIHV) isokinetic resistance exercise
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High intensity/low volume (HILV) isokinetic resistance exercise
Number of subjects: 10
Study: 15199365

Group type: EXPERIMENTAL
Intervention: PPARalpha polymorphism L162V in patients with DM‐2
Number of subjects: 842

Group type: COMPARATOR
Intervention: PPARalpha polymorphism L162V in nondiabetic controls
Number of subjects: 842
Study: 11777990

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 0
Study: 9658293

Group type: EXPERIMENTAL
Intervention: Candela laser lithotripsy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electrohydraulic lithotripsy (EHL)
Number of subjects: 24
Study: 7653447

Group type: EXPERIMENTAL
Intervention: Pravastatin, 40 mg/day, for > or = 5 years
Number of subjects: 9014

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study: 2644748

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg.kg‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.1 mg.kg‐1)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Atracurium (0.1 mg.kg‐1) - up to 8 incremental doses
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pancuronium (0.015 mg.kg‐1) - maximum of 4 increments
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 59
Study: 729619

Group type: EXPERIMENTAL
Intervention: 120 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 150 mg pseudoephedrine capsules every twelve hours for seven consecutive days
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (implied control)
Number of subjects: 33
Study: 31910395

Group type: EXPERIMENTAL
Intervention: Superimposed technique (ST)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electrical muscle stimulation (EMS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both ST and EMS
Number of subjects: 50
Study: 31450171

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg/day)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Methotrexate (40 mg/m2/week)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 480

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 480
Study: 27634384

Group type: EXPERIMENTAL
Intervention: Cladribine
Number of subjects: 1319

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1319
Study: 26347398

Group type: EXPERIMENTAL
Intervention: ECP at 300mmHg (full pressure)
Number of subjects: 23

Group type: COMPARATOR
Intervention: ECP at 75mmHg (sham pressure)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: ECP (both groups)
Number of subjects: 23
Study: 22741619

Group type: EXPERIMENTAL
Intervention: Quetiapine (200 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21275922

Group type: EXPERIMENTAL
Intervention: Oral contraceptive (OC) treatment during the active hormone phase (OC phase)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Non-OC phase (hormone-free phase)
Number of subjects: 15
Study: 19111408

Group type: EXPERIMENTAL
Intervention: ESR2 G‐G‐G haplotype (major allele for all polymorphisms)
Number of subjects: 561

Group type: COMPARATOR
Intervention: Polymorphisms rs1271572, rs1256049, rs4986938
Number of subjects: 561